|
Exjade, the new hope for thalassemia |
|
|
|
|
Thursday, 19 January 2006 |
Exjade® (Deferasirox), the breakthrough once-daily iron chelator from Novartis has received US FDA approval on last November. Exjade is an easy to administer novel oral iron chelator, Exjade is taken once daily, after dispersing tablets in a glass of water or orange juice (100-200 ml). Exjade well tolerated, safe and effective in reducing total body iron in patients with thalassemia. Read more...
|